By AqVida GmbH
To get in touch with AqVida reports high interest in oncology at CPhI Barcelona, simply fill out the form below.
Subscribe to Supplier
AqVida reports high interest in oncology at CPhI Barcelona
Hamburg, Germany: – Innovative German oncology generics specialist AqVida has reported high interest at Europe’s largest pharma trade show, CPhI Worldwide, in its existing portfolio and the New Generic Generation of oncology drugs coming up soon, including Imatinib and Sunitinib.
Imatinib and Sunitinib capsules target patent expiries in 2016 and 2021 respectively, with backward integrated API produced in patent-free zones for targeting sales into territories where no patent applies. Aqvida’s parenteral forms will be produced in AqVida’s highly automated ‘Zero Loss’ production facility now being commissioned near Hamburg.
“We would like to thank the many delegates who visited us at Booth C60 in Hall 7 at Fira de Barcelona,” said AqVida’s Commercial Director, Jürgen Lehmberg.
“CPhI 2016 is now confirmed as our most successful showing yet, with many fruitful discussions with partners from Europe, Latin America, Middle East, Africa and South East Asia on collaborations and building long-term relationships,” said Mr. Lehmberg.
“Besides our successfully licensed portfolio of parenteral forms, visitors were particularly interested in our rapid progress towards Sunitinib, a generic version of Sutent® which we manufacturing in a patent-free zone,” he said.
“We were also able to reveal that we are now preparing to launch Imatinib as a generic version of Gleevec® as soon as the patent expires later this year. We also have Sunitinib, capsules in 12.5mg, 25mg, 37.5mg and 50mg strengths under registration and Nilotinib (generic Tasigna®) 150mg and 200mg capsules under development,” said Mr. Lehmberg.
AqVida CEO and Founder Wolfgang Heinze, who was also part of the team at CPhI, commented: “We were able to present several opportunities available for out-licensing of Imatinib, Sunitinib and a range of other products, depending on client portfolio and market stance,” said Mr. Heinze.
Solid dosage forms exhibited by AqVida at CPhI Worldwide 2016 included Azathioprine film-tablets in 25mg and 50mg formats, along with Imatinib capsules in 100mg, 200mg with line extension to 400mg.
AqVida also presented a range of parenteral and injectable forms, including infusion solutions of Docetaxel, Epirubicin, Irinotecan, Oxaliplatin and Paclitaxel.
It also showed Gemcitabine lyophilisate powder in 200mg, 1g and 2g strengths along with Filgrastim as a solution for injection in 75mcg, 150mcg, 300mcg and 480mcg strengths for application outside EU-regulated markets.
A further highlight of the AqVida display was presentation of its recently completed innovative robotic production line in Germany. The new “Zero Loss” facility features unique engineering technology to manufacture parenteral oncology generics and antibody drug conjugates (ADCs). This facility represents a major step forward for the pharma industry, using totally robotic controlled filling processes in an isolator for parenteral cytotoxics.
“Our new production hi-tech facility is able to produce the world’s best medicines,” said Wolfgang Heinze.
“CPhI confirmed for us that more and more pharmaceutical companies, especially in Asia, MENA/GCC, Africa and South America, are looking for alternative higher quality supplies in generic oncologic drugs as regulatory requirements become increasingly stringent in Europe and beyond,” Mr. Heinze noted.
“We were able to show that AqVida is able to match these needs with EU quality products at a competitive price level and several other benefits, such as keeping inventory, short lead-time, dossier maintenance, etc.,” he concluded.
The past ten years, AqVida has built a leading position for oncology products in the German/European market and we are nearing completion of our new manufacturing line.
AqVida is a German oncology FDF manufacturer that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.
AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.
AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio.
AqVida is a pharmaceutical company with an impressive track record in fulfilling all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.
AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organization, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.